Drug or treatment
Fostamatinib clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Fostamatinib that are recruiting, at sites in 2 countries (most in United States (4), Japan (1)). By phase: Phase 1 (4). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Fostamatinib to see if it’s safe for lung transplant patients with donor-specific antibodies | Phase 1 | Stanford, California and 3 other locations | Recruiting | Apr 29, 2025 |
| Survey on long-term use of fostamatinib for chronic idiopathic thrombocytopenic purpura | — | Tokyo and Japanese Other Cities | Recruiting | Jan 3, 2025 |
| Combining Fostamatinib with Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment | Phase 1 | La Jolla, California | Recruiting | Oct 15, 2024 |
| Ruxolitinib plus fostamatinib for adults with steroid-refractory chronic graft-versus-host disease | Phase 1 | Durham, North Carolina | Recruiting | Jan 31, 2024 |
| Evaluating the safety of fostamatinib for sickle cell disease | Phase 1 | Bethesda, Maryland | Recruiting | Jun 15, 2023 |
All recruiting trials (5)
-
Fostamatinib to see if it’s safe for lung transplant patients with donor-specific antibodies
This trial tests whether taking fostamatinib is safe for adults who have donor-specific antibodies after a lung transplant.
-
Survey on long-term use of fostamatinib for chronic idiopathic thrombocytopenic purpura
This study is looking to see how well and safely fostamatinib works for Japanese patients with chronic idiopathic thrombocytopenic purpura who are using it for the first time.
-
Combining Fostamatinib with Gemcitabine and Nab-paclitaxel for Pancreatic Cancer Treatment
This study is testing if adding a new drug called Fostamatinib to standard chemotherapy can help improve treatment outcomes for patients with operable pancreatic cancer.
-
Ruxolitinib plus fostamatinib for adults with steroid-refractory chronic graft-versus-host disease
This tests whether adding fostamatinib to ruxolitinib helps adults with chronic GvHD who haven't responded well to steroids.
-
Evaluating the safety of fostamatinib for sickle cell disease
This study is testing whether a new medication called fostamatinib is safe for adults with stable sickle cell disease and if it can help improve their blood cell function and reduce inflammation.
Quick answers
How many clinical trials of Fostamatinib are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), Japan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.